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A method for the quantitative estimation of instability with re-
spect to deamidation of the asparaginyl (Asn) residues in proteins
is described. The procedure involves the observation of several
simple aspects of the three-dimensional environment of each Asn
residue in the protein and a calculation that includes these obser-
vations, the primary amino acid residue sequence, and the previ-
ously reported complete set of sequence-dependent rates of de-
amidation for Asn pentapeptides. This method is demonstrated
and evaluated for 23 proteins in which 31 unstable and 167 stable
Asn residues have been reported and for 7 unstable and 63 stable
Asn residues that have been reported in 61 human hemoglobin
variants. The relative importance of primary structure and three-
dimensional structure in Asn deamidation is estimated.
biological clocks u proteins
The spontaneous deamidation of glutaminyl and asparaginylresidues causes experimentally and biologically important
changes in peptide and protein structures. In asparaginyl deami-
dation, the primary reaction products are aspartyl and isoaspar-
tyl. Early work on peptide and protein deamidation (1–10)
established that deamidation occurs in vitro and in vivo and
depends on primary sequence, three-dimensional (3D) struc-
ture, pH, temperature, ionic strength, buffer ions, and other
solution properties.
It was hypothesized (3, 5, 7) and then experimentally demon-
strated (2, 8, 9, 11) that deamidation can serve as a biologically
relevant molecular clock that regulates the timing of in vivo
processes. Substantial evidence supports the hypothesis that Asn
deamidation at neutral pH proceeds through a cyclic imide
reaction mechanism (12–14).
A procedure is needed whereby the stability of individual
amides in peptides and proteins can be reliably estimated.
Although it was evident to investigators 30 years ago (2–7) that
protein deamidation rates depend on primary, secondary,
tertiary, and quaternary protein structure, and numerous
examples have been found, it was not possible to devise a useful
deamidation prediction procedure until a complete library of
deamidation rates as a function of primary sequence was
available.
A suitable library of sequence-determined Asn rates has now
been published (15), and the relevance of this library has been
established (16). These rates can now be combined with 3D data
to provide a useful deamidation prediction procedure. Each
amide residue has an intrinsic sequence-determined deamida-
tion rate, which depends on charge distribution, steric factors,
and other aspects of peptide chemistry. This primary rate is
modulated by 3D structure, which usually slows the rate. In a few
instances, it increases the deamidation rate.
We have devised a simple procedure that is useful for pre-
dicting the relative deamidation rates of most protein Asn
residues. We have tested this procedure on a complete set of all
proteins for which, during a review of the literature, we found
experiments specifically identifying one or more labile Asn
residues in a protein and also a suitable 3D structure for that
same protein. Although our procedure assumes that deamida-
tion proceeds through a cyclic five-membered imide formed by
reaction of the Asn amide side chain with the nearest carboxyl-
side peptide bond nitrogen, it would likely give good results even
if the actual mechanism were different.
When sequence-dependent rates of deamidation first became
available (3–10), it was found that most protein deamidation
rates were slower than those of corresponding model peptides,
except in protein amides located in especially f lexible regions
such as those that initiate the in vivo turnover of cytochrome C
(2, 8) and aldolase (9, 11). Deamidation suppression of Asn in
a-helices has been demonstrated (15–17), and it is evident that
Asn deamidation generally depends on 3D freedom in the
peptide chain.
We have limited this Asn deamidation prediction procedure to
3D observations that can easily be made with an ordinary
personal-computer-based 3D protein structure viewer and 1–2
hours of work per protein without special computer programs or
other aids. Subtle or complicated 3D effects have, therefore,
been omitted. Although it is to be expected that sophisticated
computerized procedures for this purpose will eventually be
devised, there are not yet sufficient experimental data with
which to calibrate such procedures.
Materials and Methods
Selection of Proteins. All reports of Asn deamidation in proteins
wherein investigators identified the specific deamidating Asn
residue were gathered from the Medline and Citation Index
databases. The Brookhaven Protein Data Bank (http:yy
www.rcsb.orgypdb) was then searched for a 3D structure that
was identical in protein biological type and primary sequence to
each protein in which deamidation had been reported. Every
protein for which we found a suitable deamidation report and a
corresponding 3D structure is included herein. None have been
omitted.
In addition, 44 human hemoglobin mutations that convert
another residue into Asn and 16 mutations that change the
residue on the carboxyl side of one of the 10 wild-type Asn
residues have been reported. This set of 70 Asn residues, of which
7 have been reported to deamidate, is included.
The selected proteins and their Brookhaven Protein Data
Bank identification numbers are: rabbit aldolase 1ADO (11, 18),
human angiogenin 1B1I (19, 20), bovine calbindin 4ICB (21, 22),
pig cAMP-dependent protein kinase 1CDK (23, 24), horse
cytochrome C 2GIW (NMR) (25, 26), mouse epidermal growth
factor 1EGF (NMR) (27, 28), rat fatty acid-binding protein
1LFO (29, 30), human fibroblast growth factor 2AFG (31, 32),
Aspergillus awamorii glucoamylase 3GLY (33, 34), human
growth hormone 1HGU (35, 36), human hemoglobin 1A3N
(37–44, 45), Escherichia coli Hpr-phosphocarrier protein 1HDN
(NMR) (46, 47), human hypoxanthine guanine phosphoribosyl
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transferase 1BZY (48, 49), human insulin 2HIU (NMR) (50, 51),
mouse interleukin 1b 2MIB (52, 53), human interleukin 2 3INK
(54, 55), chicken lysozyme 1E8L (NMR) (56, 57), bovine ribo-
nuclease A 1AFK (58, 59), Ustilago sphaerogena ribonuclease U2
1RTU (60, 61), bovine seminal ribonuclease 11BG (62, 63),
human T cell surface protein CD4 1CDJ (64, 65), human
thioltransferase 1JHB (NMR) (66, 67), human triosephosphate
isomerase 1HTI (68, 69), and bovine trypsin 1MTW (70, 71).
Trypsin is included, but the reported (70) relative Asn insta-
bilities are unsuitable. Trypsin was incubated in solution for 1
year while the solution was differentiated through crystal growth
into a homogenous fraction that exhibited deamidation at three
positions. No deamidation measurements on an undifferentiated
solution were reported.
Selection of 3D Parameters. A set of observations of the 3D
environment of each Asn was selected. This set included
positions with respect to a-helical or b-sheet regions, hydrogen
bonds to the Asn, other hydrogen bonds inhibiting formation
of a succinimide intermediate, and relative freedom of the Asn
peptide backbone. These observations were made and tabu-
lated by one of us (N.E.R.) before any calculations were
carried out. The tabulated observations were not changed
after calculations began. The observations were made with
SWISS PROTEIN DATA BANK VIEWER software, StereoGraphics
ENT B and CE-3 viewer hardware (StereoGraphics Corp.,
San Rafael, CA) and a Pentium III computer with MICROSOFT
NT 4.0.
The deamidation coefficient, CD, is defined as CD 5 (0.01)
(t1/2)~ef~Cm, CSn, Sn!), where t1/2 is the pentapeptide primary struc-
ture half life (15), Cm is a structure proportionality factor, CSn is
the 3D structure coefficient for the nth structure observation, Sn
is that observation, and f(Cm, CSn, Sn) 5 Cm[(CS1)(S1) 1
(CS2)(S2) 1 (CS3)(S3) 2 (CS4,5)(S4)/(S5) 1 (CS6)(S6) 1
(CS7)(S7) 1 (CS8)(S8) 1 (CS9)(S9) 1 (CS10)(1 2 S10) 1
(CS11)(5 2 S11) 1 (CS12)(5 2 S12)]. The structure observations,
Sn, were selected as those most likely to impede deamidations,
including hydrogen bonds, a helices, b sheets, and peptide
inflexibilities. The functional form of CD assumes that each of
these structural factors is added to the reaction activation
energy.
The observed Sn were:
For Asn in an a-helical region:
S1 5 distance in residues inside the a helix from the NH2 end,
where S1 5 1 designates the end residue in the helix, 2 is the
second residue, and 3 is the third. If the position is 4 or greater,
S1 5 0.
S2 5 distance in residues inside the a helix from the COOH
end, where S1 5 1 designates the end residue in the helix, 2 is the
second residue, and 3 is the third. If the position is 4 or greater
or S1 Þ 0, then S2 5 0.
S3 5 1 if Asn is designated as completely inside the a helix,
because it is 4 or more residues from both ends. If the Asn is
completely inside, S3 5 1, S1 5 0, and S2 5 0. If S1 Þ 0 or S2 Þ
0, then S3 5 0.
For flexibility of a loop including Asn between two adjacent
antiparallel b sheets:
S4 5 number of residues in the loop.
S5 5 number of hydrogen bonds in the loop. S5 $ 1 by
definition.
For hydrogen bonds:
S6 5 the number of hydrogen bonds to the Asn side chain
CAO group. Acceptable values are 0, 1, and 2.
S7 5 the number of hydrogen bonds to the Asn side chain NH2
group. Acceptable values are 0, 1, and 2.
S8 5 the number of hydrogen bonds to the backbone N in the
peptide bond on the COOH side of Asn. Hydrogen bonds
counted in S6 or S7 are not included. Acceptable values are 0 and
1. This nitrogen is used in the five-membered succinimide ring.
S9 5 additional hydrogen bonds, not included in S6, S7, and S8,
that would need to be broken to form the succinimide ring.
For Asn situated so that no a-helix, b-sheet, or disulfide bridge
structure is between the Asn and the end of the peptide chain:
S10 5 1 if the number of residues between the Asn and the
nearest such structure is 3 or more. If the number of intervening
residues is 2, 1, or 0, or Asn not between structure and chain end,
then S10 5 0.
If the Asn lies near to any a-helix, b-sheet, or disulfide bridge
structures:
S11 5 the number of residues between the Asn and the
structure on the NH2 side, up to a maximum of 5. Values of 0,
1, 2, 3, 4, and 5 are acceptable.
S12 5 the number of residues between the Asn and the
structure on the COOH side, up to a maximum of 5. Values of
0, 1, 2, 3, 4, and 5 are acceptable.
Hydrogen bonds selected by the Swiss Protein Data Bank
(PDB) viewer were accepted if the bond length was 3.3 Å or less,
and there was room in the structure to accommodate the van der
Waals radius of the hydrogen. The Swiss PDB viewer, according
to the customary criteria, selected a helices and b sheets. All
primary structure t1/2 values were those published (15), except
for Asn with carboxyl-side Pro, Asn, or Gln and N-glycosylated
Asn. We used estimated values of t1/2 of 500, 40, 60, and 500 days
for Asn-Pro, Asn-Asn, Asn-Gln, and N-glycosylated Asn,
respectively.
Optimization of the Coefficient of Deamidation. CD values were
optimized (72, 73) by using various values for Cm and CSn to
maximize the value of the deamidation resolving power, DP. The
optimized values were Cm 5 0.48, CS1 5 1.0, CS2 5 2.5, CS3 5
10.0, CS4,5 5 0.5, CS6 5 1.0, CS7 5 1.0, CS8 5 3.0, CS9 5 2.0,
CS10 5 2.0, CS11 5 0.2, and CS12 5 0.7.
For example, the b-Lys-Asn 145-His sequence of hemoglobin
is not in an a helix or in a loop between two b sheets, so
S1 through S4 5 0, S5 5 1. There is one hydrogen bond to the
amide side chain nitrogen and one other to be broken to form
Fig. 1. Classification accuracies of the Asn residues in Tables 1 and 2 with all
possible CD division values used for the classification, excluding four Asn
marked ‡ in Table 1 and ‡ and ‡‡ in Table 2, and calculated deamidation
resolving power (DP).
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the imide, but there are none to the amide carboxyl or the back-
bone nitrogen, so S6 5 0, S7 5 1, S8 5 0, and S9 5 1. This Asn
is near the carboxyl end of the chain and one residue from an
a-helix on the amino side, so S10 5 0, S11 5 1, and S12 5 5.
The Gly-Lys-Asn-His-Gly half life (15) is 10.5 days. There-
fore, CD 5 (0.01)(10.5)e(0.48)[(1)(1)1(2)(1)1(2)(1– 0)1(0.2)(4)] 5
(0.105)e(0.48)(5.8) 5 (0.105)(16.184) 5 1.70.
The DP calculation method as developed previously for the
evaluation of quantitative procedures in diagnostic medicine (72,
73) was used as illustrated in Figs. 1–3. A total of 264 Asn
residues listed in Tables 1 and 2 were arranged in order of
calculated CD values and then divided into all possible two group
sets arising from division at all possible CD values. The errors at
these division points for the optimized parameters are graphed
in Fig. 1. Figs. 2 and 3 show graphs for primary structure and 3D
structure alone. If the classification of Asn stabilities were
perfect, then the graphs in Figs. 1–3 would be straight lines along
the axes, appearing as points in the origin. If there were no
correlation between the calculations and the experimental data, the
graphs would be along the diagonal lines. DP is defined as the
percentage of the area between the diagonal and the origin that has
been successfully removed by the deamidation estimation
procedure.
Two of the hemoglobin Asn mutations involve large undeter-
mined structural changes in the protein, one by a frame-shift and
the other causing the loss of the heme group, so suitable 3D
criteria could not be tabulated. 3D effects apparently markedly
accelerate deamidation of Asn 54 in cytochrome C and Asn 88
in interleukin 2. These four Asn were not used in calculating DP.
Reliability of the Coefficient of Deamidation. In addition to DP, the
Asn ranks within each protein as shown in Table 1 are especially
interesting because these ranks avoid the complication that the
different proteins were subjected to a wide variety of differing
deamidating conditions. All 70 Asn in the hemoglobin set shown
in Table 2 were incubated in vivo at 37°C for an average of 60 days
in human blood.
Although the Asn residues designated as deamidating have
been reported from experiments, those designated as undeami-
dating depend on negative results. In many cases, ammonia
evolution or protein separation experiments have shown that
additional unstable amides are present in these proteins. This is
reflected in the asymmetry seen in Fig. 1, wherein some of the
‘‘% deamidated Asn incorrect’’ at low CD values are probably
correctly assigned but not yet reported. We expect that some of the
Asn residues listed in Tables 1 and 2 with low CD values will
eventually be found to significantly deamidate.
The values of CD depend on 18 x-ray diffraction and 6 NMR
structures. Although the deamidation of aldolase Asn-360 is
known to be entirely sequence controlled in vivo and in vitro with
no 3D suppression (9, 15, 16), the x-ray crystal structure shows
one suppressing hydrogen bond. This aldolase CD is, therefore, 0.22.
It should be 0.08. Solution structures are best used when available.
Multiplication of the coefficient of deamidation (CD) by 100
provides a semiquantitative prediction of Asn deamidation
half times in 37°C, pH 7.4, 0.15 M TriszHCl buffer, even though
CD does not include all aspects of 3D structure. Table 3 lists
those proteins for which experimental deamidation half times
at 37°C, pH at or near 7.4, but with a wide range of buffer types
and solution properties have been reported (2, 31, 39, 50,
74–78) vs. the corresponding values of (100)(CD) for those
Asn. The overall differences in Table 3 are well within the
range expected from variations in buffer type and other solvent
conditions.
It is customary to guess which Asn residues may easily
deamidate on the basis of primary structure. With the complete
rate table (15) and 33 of the deamidating Asn residues in our
data set, the sequence assumptions that these types of Asn
residues easily deamidate are 49% in error even in the very
unstable Asn-Gly sequences, 70% in the Asn-Ser and Asn-His
sequences, 83% in Asn-Ala and Asn-Asp, and 91% in Asn-Gln,
Asn-Lys, and Asn-Tyr. The converse nondeamidation assump-
tions are 51%, 30%, 17%, and 9% in error, respectively (see Fig.
4). In comparison, Fig. 1 shows that a division criterion of CD #
3 leads to less than 6% error in classification of all easily
deamidating and all relatively stable Asn residues, simulta-
neously. A criterion of CD # 5 includes 100% of deamidating Asn
residues, except for Asn 54 in cytochrome C and Asn 88 in
interleukin 2.
Fig. 2. Tabulation and calculation as in Fig. 1, but by using only the primary
structure part of the coefficients CD. Cm 5 0.
Fig. 3. Tabulation and calculation as in Fig. 1, but by using only the 3D
structure part of the coefficients CD. All t1/2 5 1.
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Deamidation Index. The initial deamidation of a protein at neutral
pH causes a unit decrease in charge. We define ID 5
[((CDn)
21]21, where CDn is CD for the nth Asn residue, as the
protein “deamidation index.” Therefore (100)(ID) is an estimate
of the initial single-residue deamidation half time for the protein
with all Asn residues considered, as shown in Tables 1 and 2.
Results and Discussion
This calculation method, based on the sequence-controlled
deamidation rates of Asn model peptides and simple aspects of
the Asn 3D environment in proteins, permits a useful estimation
of the instability with respect to deamidation of Asn in proteins.
Table 1. Ordered deamidation coefficients and experimentally determined deamidating Asn residues in 23 proteins
Squares designate Asn reported as deamidated. designates Deamidation Index, ID.
‡These two unshaded squares designate unusual protein structures that accelerate deamidation.
‡‡Uses primary t1/2 from ref. 8.
‡‡‡Uses primary t1/2 from ref. 16.
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For a diverse group of protein types, this method is at least 94%
reliable, as illustrated in Fig. 1. This reliability is underestimated,
because the evaluation in Fig. 1 considers all of these protein amides
simultaneously even though their deamidations were observed
under a wide variety of experimental conditions. Moreover, some
experimentally known Asn instabilities in these proteins have not
yet been characterized, so the data used in Fig. 1 incorrectly classify
some Asn as stable that are actually unstable.
When used to determine the reportedly most unstable Asn
residues within a single protein as illustrated in Tables 1 and 2,
this method correctly identifies the most unstable Asn residue
for 31 of 36 residues in 24 proteins and, in 4 of the remaining 5
cases, is in error by only one residue.
This method does not allow for special 3D structures that
change deamidation rates in unusual ways. There are still too few
reported instances of these to permit their theoretical estima-
tion. In two Asn sequences encountered here, Lys-Asn 54-Lys in
cytochrome C and Ser-Asn 88-Ileu in interleukin 2, the reported
experimentally determined protein rates are faster than the
sequence determined rates. Also, in two instances, Met-Asn
15-Gly in triosephosphate isomerase (79) and Lys-Asn 54-Lys (7)
in cytochrome C, deamidation takes place after a prior deami-
dation of the protein changes the structure in an accommodating
way. Although this calculation method cannot predict these
special effects, it aids in their recognition.
Finally, this procedure provides a semiquantitative answer to
a previously unanswered question. What are the relative con-
tributions to deamidation rates in proteins from primary struc-
ture and 3D structure? Figs. 1–3 serve as a reasonable basis for
estimating that Asn deamidation in proteins is, on average,
determined approximately 60% by primary structure and 40% by
3D structure. These percentages apply to 3D effects that dimin-
ish deamidation rates below those of primary structure alone. In
2 cases out of 36—about 6% of deamidating Asn and 1% of all
Asn examined here—3D structure is reported to actually accel-
erate deamidation.
These calculations demonstrate that most deamidation rates
of Asn residues in proteins are approximately equal to the
sequence-controlled rates modulated through slowing by 3D
structure. The modulated values can be estimated by a remark-
ably simple calculation. We are now experimentally determining
a complete deamidation rate table for Gln residues in pentapep-
tides, which should allow a similar treatment for Gln residues in
proteins. Values of ID and CD for many other proteins are
available at www.deamidation.org.
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Fig. 4. Percentages of deamidating Asn residues listed in Tables 1 and 2 that
would be correctly guessed by simply assuming that Asn residues with COOH-
side Gly, His, Ser, Ala, Asp, Gln, Lys, or Tyr deamidate vs. average pentapeptide
deamidation half times (15) for those specific Asn sequences.
Table 3. Deamidation half times in days at 37°C, pH 7.4 vs.
estimates by (100)(CD)
Experimental* Calc (100)(CD)
Hpr–phosphocarrier protein (Asn-38) 10 57
Angiogenin (Asn-61 and Asn-109) 23† 17 ‡
Hemoglobin (a-Asn-50) 25 18
Growth hormone (Asn-149 and Asn-152) 29† 48
Hpr–phosphocarrier protein (Asn-12) 31 21
Triose phosphate isomerase (Asn-71) 38 78
Hemoglobin (b-Asn-82) 42 19
Fibroblast growth factor (Asn-7) 60 64
Hemoglobin (b-Asn-80) 71 173
Ribonuclease A (Asn-67) 64 85 ‡
Insulin (B-Asn-3) 135 117
*Buffer conditions vary. pHs at or close to 7.4.
†Reported rate for sum of both Asn residues.
‡Buffer (Tris) identical to that of model peptides used to calculate CD.
Table 2. Ordered deamidation coefficients for 70 Asn residues in
wild-type and mutant human hemoglobins and experimentally
determined deamidating Asn residues
‡Frame-shift mutation and ‡‡heme loss mutation, so 3D structures are un-
known, and CD derived from wild-type hemoglobin is not applicable. Squares
designate Asn reported as deamidated. designates wild-type deamida-
tion index, ID.
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